Cargando…
Hydroxychloroquine in SLE: old drug, new perspectives
Antimalarial agents have long been used in the treatment of autoimmune diseases, despite uncertainty regarding the exact mechanisms underlying their various effects. Growing evidence that these drugs offer protection from major infections could stimulate more research into these mechanisms, with pos...
Autor principal: | Dörner, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097534/ https://www.ncbi.nlm.nih.gov/pubmed/20046202 http://dx.doi.org/10.1038/nrrheum.2009.235 |
Ejemplares similares
-
Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021) -
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE
por: Xie, Han, et al.
Publicado: (2023) -
Mechanisms of B cell autoimmunity in SLE
por: Dörner, Thomas, et al.
Publicado: (2011) -
Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
por: Basta, Fabio, et al.
Publicado: (2020) -
Hydroxychloroquine Use Is Not Associated With QTc Length in a Large Cohort of SLE and RA Patients
por: Park, Elizabeth, et al.
Publicado: (2021)